Ginkgo Bioworks

Market position

Ginkgo describes itself as pioneering autonomous labs for bioengineering across biopharma, agriculture and industrial biotech, and states it serves over 130 customers. Before going public it was described as one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019, and merged with a SPAC at a $17.5 billion valuation in 2021. Its 2024 results show $227 million in revenue with large operating and net losses.

Third-party analysis and company materials cite a modular, high-throughput phenotyping platform that automates workflows from media preparation through multimodal analytics; software tooling such as digital twins used to model throughput and locate bottlenecks; remote design and execution of experiments via a cloud lab; and natural-language interaction with the automation stack ("Catalyst Agent"). Its historical differentiation was providing the early design stages of synthetic biology as a service so customers need not rebuild that capability internally. A reported collaboration with OpenAI applied an AI reasoning model with robotic lab access, described as exceeding existing biochemistry benchmarks by 40 percent.

Technology

Ginkgo's core technology is a robotic "Foundry" and, more recently, autonomous laboratories that replace manual benchwork, allowing scientists to order experimental work from robots using natural language. Capabilities cited include organism and cell engineering, protein engineering, nucleic acid design, cell-free systems, ultra-high-throughput screening (via FGen), adaptive laboratory evolution instruments (via Altar), real-time metabolite monitoring (via Bitome) and cell and gene therapy tools (via Circularis). With IARPA, Ginkgo worked on ENDAR (Engineered Nucleotide Detection and Ranking), a software tool to detect whether biological organisms have been genetically engineered, potentially providing early warning of bioweapons and other man-made biological threats.

Go-to-market

Ginkgo sells directly to enterprise and institutional R&D customers through consultative engagement (inbound contact forms, meeting bookings, and the Solutions and Datapoints teams that scope projects). Its funnel includes a "try before you buy" cloud-lab offering on the Boston autonomous lab that precedes sales of customer-owned autonomous labs. It has also used large multi-year partnerships with corporates (Cronos, Roche, Bayer, Synlogic), government contracts (a reported $47 million Department of Energy contract; IARPA work), spinout creation, and equity-for-services arrangements with early-stage startups through partnerships with Y Combinator and Petri.

Biopharma, agricultural and industrial biotech organizations, plus food, fragrance, cosmetics, nutrition, materials and diagnostics companies; government agencies; and early-stage biotech startups that access the platform in exchange for equity.

Geography

Headquartered in Boston, Massachusetts, with a purpose-built laboratory site in the Raymond L. Flynn Marine Park and roughly 200,000 sq ft in the Innovation and Design Building as of 2021, plus facilities in Cambridge, Massachusetts. Acquisitions extended its footprint to West Sacramento, California (former Bayer biologics R&D site), Switzerland (FGen AG) and France (Altar). One aggregator describes the workforce as global.

History

Founded in 2008 in Boston by five MIT scientists. Early public funding support came from MassVentures' START program for SBIR-funded Massachusetts companies, followed by MassVentures' first equity investment. In 2014 Ginkgo became the first biotechnology company to join the Y Combinator accelerator. Venture rounds followed from 2014 through 2020, including a $45M/$53M Series B led by Viking Global in 2015, a $100M Series C in 2016, a $280M Series D in 2017, a $290M Series E in 2019 and a $70M round in 2020. In 2019 the company was valued at $4.2 billion and raised $290 million in September and $350 million in October. In 2020 Ginkgo agreed to acquire Novogy's Microbial Engineering Platform assets and bought $25 million of property from Marcus Partners in the Raymond L. Flynn Marine Park for a 219,000 sq ft laboratory building. On 11 May 2021 Ginkgo announced a SPAC merger with Soaring Eagle at a $17.5 billion valuation; it adopted the NYSE ticker "DNA" (previously used by Genentech) and began trading on 17 September 2021. Growth through 2021 was attributed to venture funding and entry into COVID-19 testing. Baillie Gifford became the largest shareholder (15%) after purchasing 167.75 million shares on 31 March 2022. A 2022 acquisition wave included FGen AG, Bitome assets, Zymergen ($300 million, all-stock), Bayer's West Sacramento biologics R&D site, Altar and Circularis. In Q1 2026 the company reported completing the divestiture of its Biosecurity business while continuing to scale its autonomous lab.

Risks & controversies

In October 2021 a market research firm published a report alleging Ginkgo embellished its revenue through a scheme heavily reliant on related-party transactions; the report prompted an inquiry by the U.S. Department of Justice. In November 2021 shareholders sued, alleging the company misrepresented its revenue sources in statements about the SPAC merger. As of 2021 the company could not name a single significant product manufactured and sold using its organisms. In March 2023 the former Attorney General of Louisiana launched an investigation into Ginkgo's officers and directors (sourced on Wikipedia to a self-published source). The company also reports large operating and net losses (−$560M and −$547M in 2024) relative to $227M of revenue.